2547
ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
 ARDS: Effect; the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3: Treatment; infliximab: Treatment.Drug; gemtuzumab: Treatment.Drug; ozogamicin: Treatment.Drug; OKT3: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 ARDS: Effect; the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3: Treatment; infliximab: Treatment.Drug; gemtuzumab: Treatment.Drug; ozogamicin: Treatment.Drug; OKT3: Treatment.Drug